Company intelligence / Profile preview
Gland Pharma
- Ownership
- Private
- Employees
- ~4200
- Development stage
- Commercial
Overview
Gland Pharma has a strong track record in the development and commercialization of complex generic injectable drugs. The company supplies its products globally across 60+ countries with regulatory approvals from major agencies including USFDA and EMA. Its portfolio includes both hospital generics and specialty injectables in oncology and ophthalmology. It has pioneered several first-to-file or NCE–1 launches in regulated markets. No proprietary clinical trial results are published as it focuses on generics.
- Therapeutic areas
- OtherOncologyCardiovascularInfectious Diseases
- Modalities
- Sterile injectablesSmall moleculeBiologic (including peptides, long acting injectables, suspensions, hormonal products)Oncology formulations
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Gland Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gland Pharma.